Consequently, an international group of experts established MAFLD diagnostic criteria for pediatric patients that included histological, imaging (ultrasound), or blood biomarker (e.g., ALT) evidence of steatosis, in association with excess adiposity, the presence of prediabetes or T2DM, or evidence of metabolic dysregulation. The gene discussed is GPT; the disease is prediabetes syndrome.